Skip to content

Ionis Pharmaceuticals IONS Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies

Allegion logo
AllegionALLE
$525K+291%
Aptiv logo
AptivAPTV
-$283M-261%
Acuity Brands logo
Acuity BrandsAYI
-$4.75M-439%
Kimberly-Clark logo
Kimberly-ClarkKMB
-$35.25M-205%
ATI logo
ATIATI
$9.78M+183%
Arch Capital Group logo
Arch Capital GroupACGL
-$1.53M-333%

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
Ionis Pharmaceuticals (IONS) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of -$138K in Q1 2026.
How has Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax changed year-over-year?
Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax decreased by 159.5% year-over-year, from $232K to -$138K.
What is the long-term trend for Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
Over 2 years (2023 to 2025), Ionis Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax has grown at a 45.7% compound annual growth rate (CAGR), from $351K to $745K.
What does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax mean?
Gains or losses caused by changes in currency exchange rates.
How do you interpret other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
High volatility indicates significant exposure to foreign currency fluctuations.
How does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax compare across companies?
Standard for multinational companies with international operations.